Global Economic Uncertainty and Geopolitical Risks: The ongoing Middle East conflict and downgraded global growth forecasts from the IMF create a risk-off sentiment in the market. This could lead to reduced investor appetite for growth-oriented biotech stocks like Ardelyx, potentially impacting valuation and access to capital for research, development, and commercialization.

Interest Rate Environment and Cost of Capital: While not explicitly stated as interest rate changes, the strength of the US economy (e.g., job additions) influences monetary policy. A tighter monetary environment or higher interest rates could increase borrowing costs for Ardelyx, which relies on external funding for its pipeline and product launches, making future equity financing less attractive.

Healthcare Policy and Reimbursement Landscape: As a biopharmaceutical company commercializing specialty medications (IBSRELA and XPHOZAH), Ardelyx's revenue and profitability are significantly tied to the evolving healthcare policy and reimbursement environment. Changes in drug pricing regulations, insurance coverage, or patient access programs could directly impact the uptake and financial success of its products.